KALA BIO Inc
KALA0.640USD
+0.070+12.32%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.76MMarket Cap
LossP/E TTM
More Details of KALA BIO Inc Company
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
KALA BIO Inc Info
Ticker SymbolKALA
Company nameKALA BIO Inc
IPO dateJul 20, 2017
CEOLazar (David Elliot)
Number of employees38
Security typeOrdinary Share
Fiscal year-endJul 20
Address1167 Massachusetts Avenue
CityARLINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02476
Phone17819965252
Websitehttps://www.kalarx.com/
Ticker SymbolKALA
IPO dateJul 20, 2017
CEOLazar (David Elliot)
Company Executives of KALA BIO Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Darius Kharabi
Mr. Darius Kharabi
Chief Business Officer
Chief Business Officer
41.77K
-33.25%
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Director
Director
22.77K
-15.13%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director
3.05K
--
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Independent Director
2.71K
+935.11%
Dr. Marjan Farid, M.D.
Dr. Marjan Farid, M.D.
Independent Director
Independent Director
2.45K
--
Mr. David Elliot Lazar
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
--
--
Mr. Mark T. Iwicki
Mr. Mark T. Iwicki
Director
Director
--
--
Dr. Kim Brazzell, Ph.D.
Dr. Kim Brazzell, Ph.D.
Head of Research and Development, Chief Medical Officer
Head of Research and Development, Chief Medical Officer
--
--
Mr. C. Daniel Myers
Mr. C. Daniel Myers
Independent Director
Independent Director
--
--
Ms. Taylor Steiner
Ms. Taylor Steiner
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Darius Kharabi
Mr. Darius Kharabi
Chief Business Officer
Chief Business Officer
41.77K
-33.25%
Mr. Todd M. Bazemore
Mr. Todd M. Bazemore
Director
Director
22.77K
-15.13%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Lead Independent Director
Lead Independent Director
3.05K
--
Mr. Howard B. (Howie) Rosen
Mr. Howard B. (Howie) Rosen
Independent Director
Independent Director
2.71K
+935.11%
Dr. Marjan Farid, M.D.
Dr. Marjan Farid, M.D.
Independent Director
Independent Director
2.45K
--
Mr. David Elliot Lazar
Mr. David Elliot Lazar
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
Chairman of the Board, Chief Executive Officer, Director, Principal Executive Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Oxford Finance LLC
19.73%
SR One Capital Management, LP
4.19%
Baker Bros. Advisors LP
3.78%
Woodline Partners LP
3.01%
The Vanguard Group, Inc.
2.57%
Other
66.71%
Shareholders
Shareholders
Proportion
Oxford Finance LLC
19.73%
SR One Capital Management, LP
4.19%
Baker Bros. Advisors LP
3.78%
Woodline Partners LP
3.01%
The Vanguard Group, Inc.
2.57%
Other
66.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor
22.85%
Hedge Fund
8.59%
Venture Capital
4.19%
Individual Investor
2.11%
Investment Advisor/Hedge Fund
1.33%
Research Firm
0.05%
Bank and Trust
0.01%
Other
60.87%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
66
3.53M
51.06%
-952.30K
2025Q2
83
4.39M
68.04%
+246.42K
2025Q1
87
4.55M
70.65%
+406.89K
2024Q4
88
3.89M
64.57%
+719.01K
2024Q3
107
2.55M
53.72%
-568.60K
2024Q2
124
2.52M
53.27%
+878.66K
2024Q1
153
1.32M
46.57%
-352.41K
2023Q4
174
1.22M
46.23%
-240.85K
2023Q3
220
1.43M
56.63%
+307.93K
2023Q2
244
1.30M
52.70%
+147.16K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SR One Capital Management, LP
598.94K
9.28%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
310.56K
4.42%
-891.34K
-74.16%
Sep 30, 2025
Woodline Partners LP
300.15K
4.28%
+41.38K
+15.99%
Jun 30, 2025
The Vanguard Group, Inc.
170.38K
2.43%
+17.60K
+11.52%
Jun 30, 2025
Adar1 Capital Management LLC
149.83K
2.13%
-149.13K
-49.88%
Jun 30, 2025
Geode Capital Management, L.L.C.
56.37K
0.8%
+1.53K
+2.80%
Jun 30, 2025
Iwicki (Mark T.)
63.69K
0.91%
-21.64K
-25.36%
Jun 24, 2025
Kharabi (Darius)
62.57K
0.89%
-5.24K
-7.73%
Jun 24, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
Date
Type
Ratio
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
Oct 20, 2022
Merger
50→1
FAQs
Who are the top five shareholders of KALA BIO Inc?
The top five shareholders of KALA BIO Inc are:
SR One Capital Management, LP holds 598.94K shares, accounting for 9.28% of the total shares.
Baker Bros. Advisors LP holds 310.56K shares, accounting for 4.42% of the total shares.
Woodline Partners LP holds 300.15K shares, accounting for 4.28% of the total shares.
The Vanguard Group, Inc. holds 170.38K shares, accounting for 2.43% of the total shares.
Adar1 Capital Management LLC holds 149.83K shares, accounting for 2.13% of the total shares.
SR One Capital Management, LP holds 598.94K shares, accounting for 9.28% of the total shares.
Baker Bros. Advisors LP holds 310.56K shares, accounting for 4.42% of the total shares.
Woodline Partners LP holds 300.15K shares, accounting for 4.28% of the total shares.
The Vanguard Group, Inc. holds 170.38K shares, accounting for 2.43% of the total shares.
Adar1 Capital Management LLC holds 149.83K shares, accounting for 2.13% of the total shares.
What are the top three shareholder types of KALA BIO Inc?
The top three shareholder types of KALA BIO Inc are:
Oxford Finance LLC
SR One Capital Management, LP
Baker Bros. Advisors LP
Oxford Finance LLC
SR One Capital Management, LP
Baker Bros. Advisors LP
How many institutions hold shares of KALA BIO Inc (KALA)?
As of 2025Q3, 66 institutions hold shares of KALA BIO Inc, with a combined market value of approximately 3.53M, accounting for 51.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -16.99%.
What is the biggest source of revenue for KALA BIO Inc?
In --, the -- business generated the highest revenue for KALA BIO Inc, amounting to -- and accounting for --% of total revenue.
